Intrexon Files $125 Million IPO
Get the latest biotech news where you want it. Sign up for the free
GenePool newsletter today!
Biotechnology company Intrexon Corp filed with U.S. regulators to raise up to $125 million in an initial public offering of common stock. The Palm Beach, Florida-based company told the U.S. Securities and Exchange Commission in a preliminary prospectus that JP Morgan and Barclays were underwriting the IPO. The filing did not reveal how many shares the company planned to sell or their expected price. (link.reuters.com/qyg59t) The company intends to list its common stock on the New York Stock Exchange under the symbol "XON". Intrexon, founded in 1998 by molecular geneticist Thomas Reed, is now controlled by Randal Kirk, who has been the chief executive of the company since 2005.
Help employers find you! Check out all the jobs and post your resume.
Biotechnology company Intrexon Corp filed with U.S. regulators to raise up to $125 million in an initial public offering of common stock. The Palm Beach, Florida-based company told the U.S. Securities and Exchange Commission in a preliminary prospectus that JP Morgan and Barclays were underwriting the IPO. The filing did not reveal how many shares the company planned to sell or their expected price. (link.reuters.com/qyg59t) The company intends to list its common stock on the New York Stock Exchange under the symbol "XON". Intrexon, founded in 1998 by molecular geneticist Thomas Reed, is now controlled by Randal Kirk, who has been the chief executive of the company since 2005.
Help employers find you! Check out all the jobs and post your resume.